Insertion of regulation 43A (approved country for import)U.K.
19. After regulation 43 insert—
“Approved country for import
43A.—(1) The licensing authority must publish a list of countries which it is satisfied have a regulatory framework applicable to investigational medicinal products exported to [F1Great Britain] that is equivalent to the regulatory framework in [F1Great Britain], in that the respective control and enforcement activities in those countries ensure an equivalent level of protection of public health.
(2) In order to determine whether a country should be included in the list referred to in paragraph (1), the licensing authority may, in particular, take into account—
(a)the country's system for ensuring that each batch of an investigational medicinal product has been manufactured and checked in accordance with the requirements of its legislation and any authorisation in respect of the clinical trial in which the product is to be used;
(b)the country's rules for good manufacturing practice;
(c)the regularity of inspections to verify compliance with good manufacturing practice;
(d)the effectiveness of enforcement of good manufacturing practice;
(e)the regularity and rapidity of information provided by that country relating to non-compliant manufacturers of investigational medicinal products;
(f)any on-site review of that country's regulatory system undertaken by the licensing authority;
(g)any on-site inspection of a manufacturing site in that country observed by the licensing authority; and
(h)any other relevant documentation available to the licensing authority.
(3) The licensing authority must—
(a)review the countries it has included in the list referred to in paragraph (1) to determine if it is still satisfied that the country should remain on that list, and if it is not so satisfied, remove that country from the list; and
(b)undertake such a review at least every three years beginning with the date on which that country is included in that list.”.
Textual Amendments
F1Words in reg. 19 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 5
Commencement Information
I1Reg. 19 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1